MediPoint: HPV and EBV Tests - Global Analysis and Market Forecasts

MediPoint: HPV and EBV Tests - Global Analysis and Market Forecasts

Summary

HPV and EBV Tests include -
- HPV Tests
- EBV Tests

Growth in the HPV and EBV Tests market is driven by -
- Improving screening and treatment of pre-cancer amongst women.
- Diagnostic cytology improvements.

The global market for HPV and EBV Tests is led by -
- Abbott
- Bio-Rad
- Hologic
- Qiagen
- Roche

Scope

- Competitive assessment: Currently marketed HPV and EBV Tests and evolving competitive landscape
- In-depth analysis of unmet needs and adoption trends of different HPV and EBV Tests
- Insightful review of the key industry drivers, opportunities, restraints and challenges.
- Annualized total HPV and EBV Tests market revenue by segment and market outlooks from 2017-2024.
- Other key topics covered include strategic competitive assessment, identification of unmet needs, and market dynamics.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the HPV and EBV Tests market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HPV and EBV Tests market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track device sales in the global and country-specific HPV and EBV Tests market from 2017-2024.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents
1 About the Authors 2
2 Table of Contents 3
2.1 List of Tables 6
2.2 6
3 Executive Summary 7
3.1 Overview 7
3.2 Market Dynamics 13
3.3 Key Players in the Market 14
3.4 Market Future Outlook 14
4 Introduction 15
4.1 Catalyst 15
4.2 Related Reports 15
4.3 Upcoming Related Reports 15
5 Market Outlook 16
5.1 Procedure Trends 16
5.2 Revenue Trends 22
5.3 Company Share Analysis 27
6 Market Access 30
6.1 Regulatory Issues 30
6.1.1 North America 30
6.1.2 Europe 34
6.1.3 APAC 54
6.1.4 South America 61
6.1.5 Middle East and Africa 64
6.2 Pricing Trends 71
6.2.1 North America 71
6.2.2 Europe 72
6.2.3 APAC 74
6.2.4 South America 75
6.2.5 Middle East and Africa 75
7 Opportunities, Unmet Needs and Barriers 76
7.1 Opportunities 76
7.1.1 Improving screening and treatment of pre-cancer among women 76
7.1.2 Sensitivity and Specificity 76
7.1.3 Diagnostic cytology improvements 76
7.2 Unmet Needs 76
7.2.1 Point of care testing 76
7.2.2 Lack of epidemiological studies for underdeveloped regions 77
7.2.3 Test and testing guidelines for Men 77
7.3 Barriers 77
7.3.1 Patient education 77
7.3.2 Reimbursement 77
7.3.3 Not approved for primary test 78
8 Market Insights 79
8.1 North America 79
8.1.1 Canada 79
8.1.2 Mexico 79
8.1.3 US 79
8.2 Europe 80
8.2.1 Denmark, Finland, Norway, and Sweden 80
8.2.2 Belgium, France, and Netherlands 80
8.2.3 Germany and Switzerland 81
8.2.4 UK and Ireland 81
8.2.5 Italy, Portugal, and Spain 81
8.2.6 Austria, Czech Republic, Hungary, and Poland 82
8.2.7 Greece, Russia, and Turkey 82
8.3 APAC 82
8.3.1 Australia and New Zealand 82
8.3.2 China and Taiwan 83
8.3.3 India 83
8.3.4 Japan 83
8.3.5 South Korea 84
8.4 South America 84
8.4.1 Brazil 84
8.4.2 Argentina and Chile 84
8.5 Middle East and Africa 85
8.5.1 Israel 85
8.5.2 South Africa 85
8.5.3 Egypt, Saudi Arabia, and United Arab Emirates 85
9 Competitive Assessment 87
9.1 Overview 87
9.2 Mergers and Acquisitions 87
9.3 Abbott 87
9.3.1 Overview 87
9.3.2 Portfolio Assessment 88
9.3.3 Competitive Positioning 88
9.4 Bio-Rad 89
9.4.1 Overview 89
9.4.2 Portfolio Assessment 89
9.4.3 Competitive Positioning 89
9.5 Hologic 90
9.5.1 Overview 90
9.5.2 Portfolio Assessment 91
9.5.3 Competitive Positioning 91
9.6 Qiagen 92
9.6.1 Overview 92
9.6.2 Portfolio Assessment 92
9.6.3 Competitive Positioning 92
9.7 Roche 93
9.7.1 Overview 93
9.7.2 Portfolio Assessment 94
9.7.3 Competitive Positioning 94
9.8 Other Players 95
10 Appendix 96
10.1 Bibliography 96
10.2 Abbreviations 96
10.3 Methodology 104
10.3.1 Overview 104
10.3.2 Coverage 104
10.3.3 Secondary Research 104
10.3.4 Forecasting Methodology 105
10.3.5 Primary Research Summary 106
10.4 About MediPoint 107
10.5 About GlobalData 107
10.6 Contact Us 107
10.7 Disclaimer 108

List Of Tables

Table 1: Key Metrics in the Global HPV and EBV Market 7
Table 2: North America HPV & EBV Tests Volume Forecast, 2015-2024 (in thousands) 16
Table 3: Europe HPV & EBV Tests Volume Forecast, 2015-2024 (in thousands) 16
Table 4: APAC HPV & EBV Tests Volume Forecast, 2015-2024 (in thousands) 19
Table 5: South America HPV & EBV Tests Volume Forecast, 2015-2024 (in thousands) 20
Table 6: Middle East and Africa HPV & EBV Tests Volume Forecast, 2015-2024 (in thousands) 21
Table 7: North America HPV & EBV Tests Revenue Forecast ($M), 2015-2024 22
Table 8: Europe HPV & EBV Tests Revenue Forecast ($M), 2015-2024 22
Table 9: APAC HPV & EBV Tests Market Revenue Forecast ($M), 2015-2024 25
Table 10: South America HPV & EBV Tests Revenue Forecast ($M), 2015-2024 26
Table 11: Middle East and Africa HPV & EBV Tests Revenue Forecast ($M), 2015-2024 27
Table 12: North America HPV & EBV Tests Company Share Analysis, 2017 27
Table 13: Europe HPV & EBV Tests Company Share Analysis, 2017 28
Table 14: APAC HPV & EBV Tests Company Share Analysis, 2017 29
Table 15: South America HPV & EBV Tests Company Share Analysis, 2017 29
Table 16: Middle East and Africa HPV & EBV Tests Company Share Analysis, 2017 29
Table 17: North America HPV & EBV Average Selling Price Forecast ($),2015-2024 71
Table 18: Europe HPV & EBV Tests Average Selling Price Forecast ($),2015-2024 72
Table 19: APAC HPV & EBV Tests Average Selling Price Forecast ($),2015-2024 74
Table 20: South America HPV & EBV Tests Average Selling Price Forecast ($),2015-2024 75
Table 21: Middle East and Africa HPV & EBV Tests Average Selling Price Forecast ($),2015-2024 75
Table 22: Mergers and Acquisitions, HPV & EBV Tests 87
Table 23:Abbott - Key Marketed Products Assessment 88
Table 24: SWOT Analysis of Abbott in the HPV & EBV Tests, 2017 88
Table 25: Bio-Rad - Key Marketed Products Assessment 89
Table 26: SWOT Analysis of Bio-Rad in the HPV & EBV Tests, 2017 90
Table 27: Hologic - Key Marketed Products Assessment 91
Table 28: SWOT Analysis of Hologic in the HPV & EBV Tests, 2017 91
Table 29: Qiagen - Key Marketed Products Assessment 92
Table 30: SWOT Analysis of Qiagen in the HPV & EBV Tests, 2017 93
Table 31: Roche - Key Marketed Products Assessment 94
Table 32: SWOT Analysis of Roche in the HPV & EBV Tests, 2017 94
Table 33: Summary of Other Players in the HPV & EBV Tests Market, 2017 95

List Of Figures

Figure 1: HPV and EBV Global Sales, by Region, 2017 and 2024 8
Figure 2: HPV and EBV Sales for North America, by Country, 2017 and 2024 9
Figure 3: HPV and EBV Sales for Europe, by Country, 2017 and 2024 10
Figure 4: HPV and EBV Sales for APAC, by Country, 2017 and 2024 11
Figure 5: HPV and EBV Sales for South America, by Country, 2017 and 2024 12
Figure 6: HPV and EBV Sales for the Middle East and Africa, by Country, 2017 and 2024 13

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available